Literature DB >> 10404215

Molecular insights into PEBP2/CBF beta-SMMHC associated acute leukemia revealed from the structure of PEBP2/CBF beta.

M Goger1, V Gupta, W Y Kim, K Shigesada, Y Ito, M H Werner.   

Abstract

PEBP2/CBF is a heterodimeric transcription factor essential for genetic regulation of hematopoiesis and osteogenesis. DNA binding by PEBP2/CBF alpha is accomplished by a highly conserved DNA binding domain, the Runt domain (RD), whose structure adopts an S-type immunoglobulin fold when bound to DNA. The supplementary subunit beta enhances DNA binding by the RD in vitro, but its role in the control of gene expression has remained largely unknown in vivo. Chromosome 16 inversion creates a chimeric gene product fusing PEBP2/CBF beta to a portion of the smooth muscle myosin heavy chain (PEBP2/CBF beta-SMMHC) that is causally associated with the onset of acute myeloid leukemia in humans. The three-dimensional structure of PEBP2/CBF beta has been determined in solution and is shown to adopt a fold related to the beta-barrel oligomer binding motif. Direct analysis of a 43.6 kD ternary RD-beta-DNA complex identifies the likely surface of beta in contact with the RD. The structure of PEBP2/CBF beta enables a molecular understanding of the capacity of PEBP2/CBF beta-SMMHC to sequester PEBP2/CBF alpha in the cytoplasm and therefore provides a molecular basis for understanding leukemogenic transformation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404215     DOI: 10.1038/10664

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  9 in total

1.  HIV type 1 viral infectivity factor and the RUNX transcription factors interact with core binding factor β on genetically distinct surfaces.

Authors:  Judd F Hultquist; Rebecca M McDougle; Brett D Anderson; Reuben S Harris
Journal:  AIDS Res Hum Retroviruses       Date:  2012-08-13       Impact factor: 2.205

2.  Auto-inhibition and partner proteins, core-binding factor beta (CBFbeta) and Ets-1, modulate DNA binding by CBFalpha2 (AML1).

Authors:  T L Gu; T L Goetz; B J Graves; N A Speck
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

Review 3.  Overview of protein structural and functional folds.

Authors:  Peter D Sun; Christine E Foster; Jeffrey C Boyington
Journal:  Curr Protoc Protein Sci       Date:  2004-05

4.  Filamin A-bound PEBP2beta/CBFbeta is retained in the cytoplasm and prevented from functioning as a partner of the Runx1 transcription factor.

Authors:  Naomi Yoshida; Takehiro Ogata; Kenji Tanabe; Songhua Li; Megumi Nakazato; Kazuyoshi Kohu; Toshiro Takafuta; Sandor Shapiro; Yasutaka Ohta; Masanobu Satake; Toshio Watanabe
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

5.  CBFB-MYH11 hinders early T-cell development and induces massive cell death in the thymus.

Authors:  Ling Zhao; Jennifer L Cannons; Stacie Anderson; Martha Kirby; Liping Xu; Lucio H Castilla; Pamela L Schwartzberg; Rémy Bosselut; P Paul Liu
Journal:  Blood       Date:  2006-12-21       Impact factor: 22.113

6.  The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain.

Authors:  Kristie L Durst; Bart Lutterbach; Tanawan Kummalue; Alan D Friedman; Scott W Hiebert
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

7.  Structural basis for the heterodimeric interaction between the acute leukaemia-associated transcription factors AML1 and CBFbeta.

Authors:  A J Warren; J Bravo; R L Williams; T H Rabbitts
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

Review 8.  Molecular biology of leukemia.

Authors:  A Jakubowiak; J Cammenga; R Sokolic; S Alvarez; G Jackson; C Hedvat; S D Nimer
Journal:  Curr Oncol Rep       Date:  2000-03       Impact factor: 5.945

Review 9.  Preleukemia and Leukemia-Initiating Cell Activity in inv(16) Acute Myeloid Leukemia.

Authors:  John Anto Pulikkan; Lucio Hernán Castilla
Journal:  Front Oncol       Date:  2018-04-26       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.